Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial GALWAY, Ireland and WASHINGTON, Oct. 28, 2024 ...

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini ... 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced ...

"Medtronic is uniquely positioned to explore the blood pressure lowering potential of multi-organ denervation. This is supported by both its intellectual property and the Symplicity Spyral ...

October 28, 2024—Medtronic announced new long-term data from the SPYRAL HTN-ON MED clinical trial of the company’s Symplicity Spyral renal denervation (RDN) system. The findings show that patients who ...

[Illustration courtesy of Medtronic] Medtronic (NYSE:MDT) today announced new, long-term study data further supporting its Symplicity Spyral renal denervation (RDN) system. Symplicity Spyral ...

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial Medtronic plc (NYSE: MDT), a global leader in healthcare ...

and for RF ablation of cavotricuspid isthmus (CTI) dependent atrial flutter. With this approval, Medtronic is now the first and only company with two PFA technologies available for patients with Afib.

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...